2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3272 Targeting the TBL1/β-catenin complex eliminates leukemia-initiating cells and remodels the leukemia microenvironment in pediatric B- and T-cell acute lymphoblastic leukemia

Samantha Hurwitz, PhD, MS, Tatiana Fourfouris, MS2, Ki Jun Lee, MS3, Alexander Lee4, Rebecca Lee5, Asher Ahdoot6, Maiah Zarrabi, MD7, Rachel Friedmann, DO8, Vic Zamloot9, Shawn Barman10, Shweta Mendiratta11, Edward Trope12, Jessica Tsai13, Fariba Navid14, Babak Moghimi, MD15, Sarah Richman16, JinSeok Park17, Deepa Bhojwani, MD18, Chintan Parekh, MD19, Oliver Bell, PhD20, Kelly street, PhD21, Aundrietta Duncan, PhD22, Stephen Horrigan, PhD23, Yong-Mi Kim, MD, PhD, MPH24
1 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
2 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
3 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
4 University of Southern California, los angeles, United States
5 University of Southern California, los angeles, United States
6 University of California, Los angeles, Los Angeles, United States
7 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
8 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
9 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
10 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
11 University of Southern California, Los Angeles, United States
12 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
13 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
14 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
15 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
16 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
17 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
18 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States
19 City of Hope, duarte, United States
20 University of Southern California, Los Angeles, United States
21 University of Southern California, Los Angeles, United States
22 Iterion Therapeutics, Houston, United States
23 Iterion Therapeutics, Houston, United States
24 Children's Hospital Los Angeles, University of Southern California, Los Angeles, United States

Treatment resistance and subsequent relapse remain major causes of mortality in pediatric B- and T-cell acute lymphoblastic leukemia (B- and T-ALL). Though it is known that aberrant Wnt/β-catenin signaling promotes leukemia cell survival, stemness, and chemoresistance, Wnt-targeted therapy is currently not available for ALL. Transducin β-like protein 1 (TBL1) is a critical cofactor of β-catenin-dependent transcription but has not been investigated as a therapeutic target in ALL.

We evaluated TBL1 expression using three independent pediatric ALL Gene Expression Omnibus (GEO) datasets. TBL1 was broadly expressed across 480 pediatric B-ALL samples representing multiple cytogenetic subtypes. In a second dataset, TBL1 expression was significantly increased at relapse compared with diagnosis in 35 matched diagnosis-relapse B-ALL patient samples and was also significantly increased in an independent cohort of 60 relapsed pediatric B-ALL cases compared with diagnostic B-ALL cases (P<0.001). In a third dataset, TBL1 expression was significantly increased in early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), an aggressive T-ALL subtype associated with poor clinical outcomes, compared with non-ETP T-ALL at diagnosis (P=0.0019). TBL1 protein expression was confirmed in 4 B-ALL cell lines, 7 patient-derived B-ALL samples, 5 T-ALL cell lines, and 8 patient-derived T-ALL samples.

Treatment of 5 B-ALL and 5 T-ALL cases with tegavivint, a first-in-class small-molecule inhibitor that disrupts the TBL1/β-catenin interaction, inhibited β-catenin-dependent transcription. Tegavivint also reduced the expression of β-catenin, TBL1, c-Myc, and other downstream Wnt targets and enhanced the activity of chemotherapy (VDA: vincristine, dexamethasone, and asparaginase), producing synergistic reductions in leukemia cell viability in 6 B-ALL and 8 T-ALL cases (Combination Index <1). In contrast, normal donor-derived T and B cells exhibited reduced sensitivity to tegavivint compared with leukemia cells at concentrations tested in leukemia cell lines, suggesting preferential activity against leukemia cells. Single-cell RNA sequencing of a relapsed patient-derived T-ALL treated with tegavivint identified preferential depletion of a CXCR3-enriched CD7?CD1a? leukemia-initiating cell (LIC) population characterized by elevated expression of downstream Wnt signaling genes, including c-Myc, Survivin, and Axin2. Combining tegavivint with chemotherapy further decreased the LIC population and CXCR3 expression in 3 T-ALL cases, suggesting preferential targeting of relapse-associated LICs.

These findings were further supported in vivo. Tegavivint significantly prolonged survival as a single agent in patient-derived relapsed B-ALL (LAX7R) and T-ALL (329X-R and HEM879) xenograft models (n=6 mice per treatment group) compared with untreated controls (329X-R: median survival time [MST], 62 vs. 32 days, P=0.0006; HEM879: MST, 134 vs. 61 days, P<0.001; LAX7R: MST, 67 vs. 35.5 days, P=0.003). The combination of tegavivint and chemotherapy eliminated leukemia-initiating activity in both T-ALL models, as demonstrated by serial transplantation: secondary recipients transplanted with bone marrow from surviving combination-treated mice remained leukemia-free, whereas recipients of bone marrow from leukemic control mice developed disease and succumbed to leukemia, indicating durable suppression of self-renewing leukemia cells. Because relapse is also influenced by the bone marrow microenvironment, we examined immune changes in a syngeneic C57BL/6 mouse model engrafted with murine BCR::ABL1-positive B-ALL (8093). Tegavivint treatment increased CD34? hematopoietic progenitor populations, reduced splenic CD4?CD25?FOXP3? regulatory T cells, and increased CD11b?F4/80? macrophage populations, consistent with remodeling of an immunosuppressive leukemia microenvironment toward one more conducive to antileukemic immunity.

Together, these findings identify TBL1 as a therapeutic vulnerability across pediatric B- and T-ALL and demonstrate that disrupting the TBL1/β-catenin complex produces antileukemic activity through multiple complementary mechanisms. In addition to suppressing Wnt signaling, tegavivint preferentially targets relapse-associated LICs and promotes an antitumor immune microenvironment, providing a strong rationale for clinical evaluation of tegavivint in pediatric relapsed and other high-risk B-/T-ALL.

Samantha Hurwitz, PhD, MS: No relevant conflicts of interest to declare.